Botanix Pharmaceuticals Limited (BXPHF)
USD 0.25
(13.64%)
USD 0.25
(13.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.73 Million AUD | 97.99% |
| 2023 | 1.88 Million AUD | -67.97% |
| 2022 | 5.88 Million AUD | 411.76% |
| 2021 | 1.15 Million AUD | -31.31% |
| 2020 | 1.67 Million AUD | -63.48% |
| 2019 | 4.58 Million AUD | 221.6% |
| 2018 | 1.42 Million AUD | 202.93% |
| 2017 | 470.6 Thousand AUD | -8.77% |
| 2016 | 515.82 Thousand AUD | 463.23% |
| 2015 | 91.58 Thousand AUD | -70.44% |
| 2014 | 309.84 Thousand AUD | -87.65% |
| 2013 | 2.5 Million AUD | 6.71% |
| 2012 | 2.35 Million AUD | 3.42% |
| 2011 | 2.27 Million AUD | 22.57% |
| 2010 | 1.85 Million AUD | 62.88% |
| 2009 | 1.13 Million AUD | 5.28% |
| 2008 | 1.08 Million AUD | 79.27% |
| 2007 | 603.47 Thousand AUD | 112.57% |
| 2006 | 283.89 Thousand AUD | 27.17% |
| 2005 | 223.24 Thousand AUD | 22.92% |
| 2004 | 181.61 Thousand AUD | -37.22% |
| 2003 | 289.29 Thousand AUD | -36.82% |
| 2002 | 457.87 Thousand AUD | 170.4% |
| 2001 | 169.33 Thousand AUD | 43.51% |
| 2000 | 118 Thousand AUD | -98.54% |
| 1999 | 8.06 Million AUD | -44.8% |
| 1998 | 14.61 Million AUD | -19.8% |
| 1997 | 18.21 Million AUD | -4.79% |
| 1996 | 19.13 Million AUD | -35.62% |
| 1995 | 29.71 Million AUD | 31.96% |
| 1994 | 22.52 Million AUD | 14.41% |
| 1993 | 19.68 Million AUD | 35.61% |
| 1992 | 14.51 Million AUD | -0.16% |
| 1991 | 14.53 Million AUD | 6.72% |
| 1990 | 13.62 Million AUD | 15.26% |
| 1989 | 11.81 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.29 Million AUD | 0.0% |
| 2024 Q4 | 3.73 Million AUD | 0.0% |
| 2024 FY | 3.73 Million AUD | 97.99% |
| 2024 Q3 | 3.73 Million AUD | 62.89% |
| 2024 Q1 | 2.29 Million AUD | -61.07% |
| 2023 Q1 | 4.01 Million AUD | -31.8% |
| 2023 Q4 | 5.88 Million AUD | 212.24% |
| 2023 Q3 | 1.88 Million AUD | -53.04% |
| 2023 FY | 1.88 Million AUD | -67.97% |
| 2023 Q2 | 4.01 Million AUD | 0.0% |
| 2022 Q1 | 2.89 Million AUD | 151.7% |
| 2022 Q4 | 5.88 Million AUD | 0.0% |
| 2022 Q3 | 5.88 Million AUD | 103.32% |
| 2022 Q2 | 2.89 Million AUD | 0.0% |
| 2022 FY | 5.88 Million AUD | 411.76% |
| 2021 Q3 | 1.15 Million AUD | -38.94% |
| 2021 Q4 | 1.15 Million AUD | 0.0% |
| 2021 Q1 | 1.88 Million AUD | 12.49% |
| 2021 Q2 | 1.88 Million AUD | 0.0% |
| 2021 FY | 1.15 Million AUD | -31.31% |
| 2020 Q3 | 1.67 Million AUD | -29.73% |
| 2020 Q1 | 2.38 Million AUD | -48.03% |
| 2020 FY | 1.67 Million AUD | -63.48% |
| 2020 Q4 | 1.67 Million AUD | 0.0% |
| 2020 Q2 | 2.38 Million AUD | 0.0% |
| 2019 Q4 | 4.58 Million AUD | 0.0% |
| 2019 FY | 4.58 Million AUD | 221.6% |
| 2019 Q1 | 1.64 Million AUD | 15.29% |
| 2019 Q2 | 1.64 Million AUD | 0.0% |
| 2019 Q3 | 4.58 Million AUD | 178.95% |
| 2018 Q2 | 846.49 Thousand AUD | 0.0% |
| 2018 Q3 | 1.42 Million AUD | 68.41% |
| 2018 Q4 | 1.42 Million AUD | 0.0% |
| 2018 FY | 1.42 Million AUD | 202.93% |
| 2018 Q1 | 846.49 Thousand AUD | 79.88% |
| 2017 Q4 | 470.6 Thousand AUD | 0.0% |
| 2017 Q3 | 470.6 Thousand AUD | 18.06% |
| 2017 FY | 470.6 Thousand AUD | -8.77% |
| 2017 Q1 | 398.59 Thousand AUD | -22.73% |
| 2017 Q2 | 398.59 Thousand AUD | 0.0% |
| 2016 FY | 515.82 Thousand AUD | 463.23% |
| 2016 Q4 | 515.82 Thousand AUD | 0.0% |
| 2015 FY | 91.58 Thousand AUD | -70.44% |
| 2015 Q4 | 91.58 Thousand AUD | 0.0% |
| 2014 Q4 | 309.84 Thousand AUD | 0.0% |
| 2014 FY | 309.84 Thousand AUD | -87.65% |
| 2013 FY | 2.5 Million AUD | 6.71% |
| 2013 Q4 | 2.5 Million AUD | 0.0% |
| 2012 Q4 | 2.35 Million AUD | 0.0% |
| 2012 FY | 2.35 Million AUD | 3.42% |
| 2011 FY | 2.27 Million AUD | 22.57% |
| 2011 Q4 | 2.27 Million AUD | 0.0% |
| 2010 FY | 1.85 Million AUD | 62.88% |
| 2010 Q4 | 1.85 Million AUD | 0.0% |
| 2009 Q4 | 1.13 Million AUD | 0.0% |
| 2009 FY | 1.13 Million AUD | 5.28% |
| 2008 FY | 1.08 Million AUD | 79.27% |
| 2008 Q4 | 1.08 Million AUD | 0.0% |
| 2007 Q4 | 603.47 Thousand AUD | 0.0% |
| 2007 FY | 603.47 Thousand AUD | 112.57% |
| 2006 Q4 | 283.89 Thousand AUD | 0.0% |
| 2006 FY | 283.89 Thousand AUD | 27.17% |
| 2005 FY | 223.24 Thousand AUD | 22.92% |
| 2005 Q4 | 223.24 Thousand AUD | 0.0% |
| 2004 Q4 | 181.61 Thousand AUD | 0.0% |
| 2004 FY | 181.61 Thousand AUD | -37.22% |
| 2003 FY | 289.29 Thousand AUD | -36.82% |
| 2003 Q4 | 289.29 Thousand AUD | 0.0% |
| 2002 Q4 | 457.87 Thousand AUD | 0.0% |
| 2002 FY | 457.87 Thousand AUD | 170.4% |
| 2001 Q4 | 169.33 Thousand AUD | 0.0% |
| 2001 FY | 169.33 Thousand AUD | 43.51% |
| 2000 Q4 | 118 Thousand AUD | 0.0% |
| 2000 FY | 118 Thousand AUD | -98.54% |
| 1999 Q4 | 8.06 Million AUD | 0.0% |
| 1999 FY | 8.06 Million AUD | -44.8% |
| 1998 FY | 14.61 Million AUD | -19.8% |
| 1997 FY | 18.21 Million AUD | -4.79% |
| 1997 Q4 | 18.21 Million AUD | 0.0% |
| 1996 FY | 19.13 Million AUD | -35.62% |
| 1995 FY | 29.71 Million AUD | 31.96% |
| 1994 FY | 22.52 Million AUD | 14.41% |
| 1993 FY | 19.68 Million AUD | 35.61% |
| 1992 FY | 14.51 Million AUD | -0.16% |
| 1991 FY | 14.53 Million AUD | 6.72% |
| 1990 FY | 13.62 Million AUD | 15.26% |
| 1989 FY | 11.81 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.575% |
| Skye Bioscience, Inc. | 14.07 Million USD | 73.479% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.676% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -361.437% |
| Qrons Inc. | 1.48 Million USD | -150.692% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8249.913% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 60.574% |
| BioStem Technologies, Inc. | 15.9 Million USD | 76.535% |
| Regen BioPharma, Inc. | 5.45 Million USD | 31.617% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.019% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.85% |
| Rebus Holdings, Inc. | 5.24 Million USD | 28.804% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13504.334% |
| Neon Bloom, Inc. | 1.22 Million USD | -204.358% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1755.684% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.999% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 61.051% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -785.285% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.542% |
| Intellipharmaceutics International Inc. | 12 Million USD | 68.922% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 3.099% |
| Mesoblast Limited | 188.44 Million USD | 98.02% |
| Marizyme, Inc. | 26.67 Million USD | 86.009% |
| Genus plc | 485 Million USD | 99.23% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 36.123% |
| Pharming Group N.V. | 244.07 Million USD | 98.471% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -85.663% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -48.314% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 1.787% |
| ContraFect Corporation | 32.53 Million USD | 88.528% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -88.364% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 2.497% |
| IMV Inc. | 37.93 Million USD | 90.161% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 68.314% |
| MultiCell Technologies, Inc. | 1617.67 USD | -230606.943% |
| ONE Bio Corp. | 27.49 Million USD | 86.427% |
| Accustem Sciences Inc. | 1.07 Million USD | -245.806% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.179% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -76.452% |
| Q BioMed Inc. | 8.13 Million USD | 54.112% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.5% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 27.477% |
| Biomind Labs Inc. | 1.49 Million USD | -149.036% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.856% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 58.726% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 79.721% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -160.282% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2526.466% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 35.047% |
| GB Sciences, Inc. | 5.41 Million USD | 31.111% |
| Alpha Cognition Inc. | 7.16 Million USD | 47.911% |
| HST Global, Inc. | 593.59 Thousand USD | -528.727% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -196.386% |
| Halberd Corporation | 728.71 Thousand USD | -412.142% |
| Enzolytics Inc. | 365.26 Million USD | 98.978% |
| Agentix Corp. | 2.51 Million USD | -48.655% |
| Resverlogix Corp. | 67.39 Million USD | 94.462% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -344.967% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.161% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -117.741% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 84.918% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 68.646% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1.826% |
| AVAX Technologies, Inc. | 3.99 Million USD | 6.552% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13437.223% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.719% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1463.802% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 0.06% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -448.163% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -37.632% |
| Kadimastem Ltd | 3.5 Million USD | -6.483% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5476.173% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -703.117% |
| LadRx Corporation | 2.2 Million USD | -69.599% |
| Cell Source, Inc. | 15.8 Million USD | 76.389% |
| Regen BioPharma, Inc. | 5.45 Million USD | 31.617% |
| NovAccess Global Inc. | 7.86 Million USD | 52.523% |
| Affymax, Inc. | 8.87 Million USD | 57.929% |
| Itoco Inc. | 1.65 Million USD | -125.755% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -81.914% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 38.303% |
| Mobile Lads Corp. | 1.31 Million USD | -184.133% |
| CytoDyn Inc. | 127.89 Million USD | 97.082% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8828.627% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -138.262% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 66.211% |
| SYBLEU INC | 681.41 Thousand USD | -447.697% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 38.838% |
| International Stem Cell Corporation | 5.27 Million USD | 29.277% |
| Bioxytran, Inc. | 3.24 Million USD | -14.851% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -496.36% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 19.169% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.896% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.238% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -84.265% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 31.872% |
| Neutra Corp. | 973.52 Thousand USD | -283.356% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.137% |
| PureTech Health plc | 125.58 Million USD | 97.028% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 0.667% |
| IXICO plc | 1.9 Million USD | -96.395% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 81.82% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.388% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Cellectis S.A. | 249.36 Million USD | 98.503% |